Adaptimmune Therapeutics plc Share Price
Equities
ADAP
US00653A1079
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.075 USD | +1.42% | +10.06% | +35.56% |
Sales 2024 * | 87.81M 7.03B | Sales 2025 * | 62.82M 5.03B | Capitalization | 275M 21.99B |
---|---|---|---|---|---|
Net income 2024 * | -88M -7.04B | Net income 2025 * | -130M -10.41B | EV / Sales 2024 * | 3.13 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.37 x |
P/E ratio 2024 * |
-2.93
x | P/E ratio 2025 * |
-2.3
x | Employees | 449 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.06% |
Latest transcript on Adaptimmune Therapeutics plc
1 day | +1.42% | ||
1 week | +10.06% | ||
Current month | -31.96% | ||
1 month | -31.96% | ||
3 months | +47.26% | ||
6 months | +95.45% | ||
Current year | +35.56% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 31/12/07 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 28/02/15 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 31/03/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 10-31 |
Andrew Allen
BRD | Director/Board Member | 57 | 31/05/23 |
David Mott
CHM | Chairman | 58 | 31/08/14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.075 | +1.42% | 1,162,546 |
25/04/24 | 1.06 | -1.85% | 565,527 |
24/04/24 | 1.08 | -5.26% | 786,554 |
23/04/24 | 1.14 | +12.87% | 1,133,640 |
22/04/24 | 1.01 | +3.41% | 694,255 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.56% | 275M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ADAP Stock